Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation

Fig. 1

Synthesis and molecular interaction analysis of KTC1101. A Synthesis pathway of KTC1101. B Evaluation of KTC1101's inhibitory activity on human Class I PI3K isoforms. C Analysis of the binding modes between KTC1101 and PI3Kα. D Analysis of the binding modes between KTC1101 and PI3Kβ. E Analysis of the binding modes between KTC1101 and PI3Kδ. F Analysis of the binding modes between KTC1101 and PI3Kγ

Back to article page

Molecular Cancer

ISSN: 1476-4598